Laurion Capital Management LP Invests $1.82 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Laurion Capital Management LP purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 98,896 shares of the biopharmaceutical company's stock, valued at approximately $1,815,000. Laurion Capital Management LP owned about 0.06% of ACADIA Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. R Squared Ltd acquired a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $47,000. KBC Group NV boosted its stake in ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 2,044 shares during the period. Globeflex Capital L P acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $168,000. Xponance Inc. bought a new position in ACADIA Pharmaceuticals during the 4th quarter worth $186,000. Finally, Vinva Investment Management Ltd bought a new position in ACADIA Pharmaceuticals during the 4th quarter worth $187,000. 96.71% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ACAD has been the topic of several research reports. Morgan Stanley restated an "equal weight" rating and issued a $20.00 price target on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. StockNews.com cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, UBS Group dropped their price objective on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 28th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $24.70.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $14.60, for a total value of $51,070.80. Following the completion of the transaction, the executive vice president now directly owns 62,773 shares in the company, valued at approximately $916,485.80. This trade represents a 5.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now directly owns 17,595 shares in the company, valued at $320,756.85. The trade was a 21.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,994 shares of company stock valued at $313,131. 26.50% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Trading Up 2.6%

NASDAQ ACAD traded up $0.44 on Thursday, hitting $17.60. 2,019,215 shares of the company's stock were exchanged, compared to its average volume of 1,853,865. The stock has a 50-day moving average of $15.80 and a 200-day moving average of $17.00. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of 22.56 and a beta of 0.47. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $20.68.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. The business had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. ACADIA Pharmaceuticals's revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 EPS. As a group, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.